Medite Cancer Diagnostics, Inc.
MDIT
$0.00
$0.000.00%
| 09/30/2018 | 06/30/2018 | 03/31/2018 | 12/31/2017 | 09/30/2017 | |
|---|---|---|---|---|---|
| Net Income | -2.07% | -58.10% | -190.79% | -214.89% | -203.02% |
| Total Depreciation and Amortization | 2.93% | 52.31% | 48.58% | 36.92% | 15.68% |
| Total Amortization of Deferred Charges | 975.26% | 1,462.86% | 475.93% | -47.24% | -127.09% |
| Total Other Non-Cash Items | -79.89% | -35.89% | -10.86% | 95.16% | 705.70% |
| Change in Net Operating Assets | -163.73% | -107.03% | 379.58% | 1,363.57% | 1,282.53% |
| Cash from Operations | -187.43% | -177.60% | -287.85% | -227.13% | -58.98% |
| Capital Expenditure | 20.30% | 20.14% | -3.45% | -16.52% | 37.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -177.78% |
| Cash from Investing | 34.16% | -217.14% | -224.32% | -16.52% | 9.55% |
| Total Debt Issued | -21.55% | 14,022.64% | 1,622.19% | 1,262.02% | 418.44% |
| Total Debt Repaid | 79.78% | -764.13% | -1,513.73% | -4,687.50% | -2,219.29% |
| Issuance of Common Stock | -93.28% | -79.45% | -6.51% | 479.31% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -582.85% | -582.85% | -582.85% | -582.85% | -210.36% |
| Cash from Financing | -31.81% | 123.58% | 161.33% | 451.14% | 328.17% |
| Foreign Exchange rate Adjustments | 180.95% | 216.13% | 192.07% | 651.85% | -1,197.06% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -195.48% | -232.83% | -127.22% | 174.74% | 739.68% |
